All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

PVRIG (COM-701 Biosimilar) Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA721905MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Q6DKI7
Target Names
PVRIG
Alternative Names
CGEN-15029 research-grade biosimilar; COM 701 research-grade biosimilar; COM701/PVRIG research-grade biosimilar ;PVRIG antibody; C7orf15 antibody; Transmembrane protein PVRIG antibody; CD112 receptor antibody; CD112R antibody; Poliovirus receptor-related immunoglobulin domain-containing protein antibody
Species Reactivity
Human
Immunogen
Recombinant Human PVRIG protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS，pH7.4
Form
Liquid
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is a research-grade biosimilar to COM-701, designed to target PVRIG (poliovirus receptor-related immunoglobulin domain-containing protein), also known as CD112R. PVRIG functions as an inhibitory immune checkpoint receptor expressed on T cells and NK cells that binds to its ligand PVRL2 (CD112), delivering suppressive signals that dampen anti-tumor immune responses. By engaging PVRL2, PVRIG inhibits T cell activation and cytotoxic function, contributing to tumor immune evasion. PVRIG is particularly relevant in immuno-oncology research, as it represents a complementary checkpoint pathway to PD-1 and TIGIT, with potential synergistic effects when targeted in combination therapies.

COM-701 is a clinical-stage therapeutic antibody that blocks the PVRIG-PVRL2 interaction, thereby restoring T cell and NK cell effector functions against tumor cells. This biosimilar antibody serves as a valuable research tool for investigating PVRIG-mediated immune regulation, exploring combination checkpoint blockade strategies, and studying tumor microenvironment dynamics. It enables researchers to evaluate immune checkpoint mechanisms and develop novel immunotherapeutic approaches across various cancer types.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Related Products

PVRIG Antibodies

PVRIG Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Cell surface receptor for NECTIN2. May act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals. Following interaction with NECTIN2, inhibits T-cell proliferation. Competes with CD226 for NECTIN2-binding.
Gene References into Functions
  1. Blockade of TIGIT or CD112R, separately or together, enhances trastuzumab-triggered antitumor response by human NK cells. PMID: 28623459
  2. Describe CD112R, a member of poliovirus receptor-like proteins, as a new coinhibitory receptor for T cells. CD112R is preferentially expressed on T cells and inhibits T cell receptor-mediated signals. PMID: 26755705
Subcellular Location
Cell membrane; Multi-pass membrane protein.
Tissue Specificity
Expressed in some types of immune cells. Expressed at low levels on the surface of freshly isolated T-cells and natural killer (NK) cells, predominantly on CD8+ T-cells (mainly memory/effector, but not naive cells) and on both CD16+ and CD16- NK cells. T-
Database Links

HGNC: 32190

OMIM: 617012

KEGG: hsa:79037

STRING: 9606.ENSP00000316675

UniGene: Hs.729356

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*